Thursday, August 31, 2006

Radilex™: Rx for Ionizing Radiation

Filed under: Nuclear Medicine , Public Health

ImmuneRegen BioSciences, a company out of Scottsdale, Arizona, has inititated a new study at the Oak Ridge National Laboratory (ORNL) to further evaluate its drug Radilex™, to support its submission to the FDA in the future. The drug is thought to be a possible treatment of the effects of acute radiation exposure. Radilex™ is an analog of Substance P (Sar9, Met (O2)11-Substance P), widely distributed throughout the body neuropeptide.

Read more about this interesting and promising product and its history on the company's product page...

                (0)